Please ensure Javascript is enabled for purposes of website accessibility

Why Intuitive Surgical Jumped 18.3% in January

By Brian Feroldi - Feb 5, 2018 at 11:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was a strong start to the year for the top dog in robotic surgery.

What happened

Shares of Intuitive Surgical (ISRG 2.69%) rose more than 18% in January, according to data from S&P Global Market Intelligence. Investors can credit the move to a strong finish in 2017 and bullish guidance for the year ahead.

So what

Intuitive kicked off January with a bang when it shared preliminary results with investors at the annual J.P. Morgan Healthcare conference. The company said it expected fourth-quarter revenue to grow by 18% year over year thanks to double-digit gains in all three of its revenue categories (services, system sales, and instruments and accessories). Management credited the gains to strong growth in system sales and 16% overall growth in procedure volume for the full year.

Two surgeons near a da Vinci system

Image source: Intuitive Surgical.

The share price remained high even after Intuitive released its official quarterly results. While revenue wasn't a surprise, management did share that its non-GAAP EPS grew by 25% year over year. What's more, investors were also pleased to hear that management had forecasted procedure growth between 11% and 15% for the upcoming year. Since management has a history of sandbagging its procedure growth guidance, that news was music to Wall Street's ears.

Now what

For 2018, management stated that they plan on placing an emphasis on growing the company's presence in international markets. China and Japan are particular areas of focus, but success in these countries is heavily dependent on government action. For that reason, CEO Guthart believes growth in these countries will take time. 

However, Intuitive also has a new challenge to overcome in the year ahead: competition. A small-cap company called TransEnterix (ASXC -4.04%) recently won FDA approval for its robotic surgery system and will be pushing hard to drive adoption. Medical device giant Medtronic (MDT 1.82%) also has plans to launch its own robotic surgery system later this year.

It is unknown at this time whether or not this incoming competition will hinder Intuitive's growth or not. However, my hunch is that the company will be just fine. Intuitive's install base is massive, and healthcare providers typically remain loyal to a brand once they have grown comfortable with one type of system. Intuitive also has a history of rolling out new systems and expanding into new procedures, so I see no reason not to assume that will be the case moving forward.

All in all, this happy shareholder continues to believe that Intuitive remains an ideal buy-and-hold investment.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
$206.10 (2.69%) $5.39
Medtronic plc Stock Quote
Medtronic plc
$91.38 (1.82%) $1.63
Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
$0.38 (-4.04%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.